Enhanced school-based surveillance of acute adverse events following immunisation with human papillomavirus vaccine in males and females, 2013

Australia was the first country to introduce a government-funded National Human Papillomavirus (HPV) Vaccination Program for females. From 2007 to 2012, the TGA captured national adverse event reports via routine passive surveillance. In 2013, the National Immunisation Program (NIP) schedule was extended to include males (12 to 13 years as standard and a two year catch-up program for males aged 14 to 15 years), with the quadrivalent HPV vaccine, Gardasil continuing to be used in the extended program. The HPV Implementation Ad-hoc Working Group of the Australian Technical Advisory Group on Immunisation (ATAGI) recommended several enhanced surveillance activities to monitor adverse events following the commencement of the extended program in February 2013.



34 pages.


If you can spare a few dollars for the creators of this website to continue their research to bring you more great content, any amount, no matter how great or small, would be greatly appreciated.

If you appreciate our work, please click here to make a donation